Literature DB >> 15943636

Reversibility of 'secondary hypercalcitoninemia' after kidney transplantation.

Kyra A Borchhardt1, Walter H Hörl, Gere Sunder-Plassmann.   

Abstract

Whether the increase of calcitonin (CT) concentration in patients with chronic kidney disease (CKD) is reversible or not after kidney transplantation is not known. We examined the effect of kidney transplantation on basal and pentagastrin-stimulated CT in CKD patients with elevated screening CT levels. Before transplantation, the median basal CT concentration of 17 patients was 31 pg/mL (13-76), and decreased to 8 pg/mL (4-28) at 23 months (2-34) after kidney transplantation (p < 0.00005). The maximum concentration of pentagastrin-stimulated CT was 63 pg/mL (25-110) before transplantation and decreased to 20 pg/mL (8-91) (p < 0.00005) thereafter. There was a linear association between CT and calcium as well as between phosphorus and parathyroid hormone at the time of screening. After transplantation, CT correlated with serum creatinine. Therefore, the increase of CT concentration in patients with impaired kidney function presumably reflects 'secondary hypercalcitoninemia' due to C-cell hyperactivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943636     DOI: 10.1111/j.1600-6143.2005.00908.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Authors:  Cléber P Camacho; Susan C Lindsey; Teresa S Kasamatsu; Alberto L Machado; João Roberto M Martins; Rosa Paula M Biscolla; Magnus R Dias da Silva; José Gilberto H Vieira; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-06-18

4.  Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease.

Authors:  Mehmet Kanbay; Myles Wolf; Yusuf Selcoki; Yalcin Solak; Mustafa Ikizek; Sema Uysal; Liviu Segall; Ferah Armutcu; Beyhan Eryonucu; Murat Duranay; David Goldsmith; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-12-01       Impact factor: 2.370

Review 5.  Biochemical Testing in Thyroid Disorders.

Authors:  Nazanene H Esfandiari; Maria Papaleontiou
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-08       Impact factor: 4.741

6.  Calcitonin Response to Naturally Occurring Ionized Hypercalcemia in Cats with Chronic Kidney Disease.

Authors:  D H N van den Broek; R F Geddes; T L Williams; Y-M Chang; J Elliott; R E Jepson
Journal:  J Vet Intern Med       Date:  2018-02-22       Impact factor: 3.333

7.  Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis.

Authors:  Irfan Vardarli; Manuel Weber; Frank Weidemann; Dagmar Führer; Ken Herrmann; Rainer Görges
Journal:  Endocr Connect       Date:  2021-03       Impact factor: 3.335

8.  Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer

Authors:  Emine Kartal Baykan; Mehmet Erdoğan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.